
A distinct family of tumors arising from the GI tract's muscle-control cells, driven by specific gene mutations and uniquely responsive to targeted therapy.
GutLiv underwrites genomic profiling access for GIST patients, helping match uncommon KIT/PDGFRA mutations to the targeted therapy most likely to work, and studying resistance pathways when tumors stop responding.